No-Cost Half & Half | MAT Waiver Virtual Training

Opioid SOR 2.0, in partnership with the Missouri Behavioral Health Council are providing an 8-hour MAT Waiver Course. This course is different from the traditional 8-hour live course, as the first 4-hours will be live through Zoom and then the last 4-hours will be individual online work.

Once you complete the first 4-hour live training, you will receive an email from AAAP with a link for the other 4-hours of individual work. Once that work is completed, they will send you a certificate of completion.

Upon completing the required courses (MD-8 hours, NP and PA-24 hours) participants will need to submit a Notice of Intent form (NOI) along with their certificate(s) of completion, provided after completing the training, which verifies that they have completed the required coursework. A link to the NOI form application will be given following the training.

AVAILABLE DATES: CLICK HERE TO REGISTER

- **Saturday, March 5, 2022 (virtual)** | 8:30a.m. - 12:30p.m. | Presenter: Dr. Evan Schwarz
- **Saturday, June 18, 2022 (virtual)** | 8:30a.m. - 12:30p.m. | Presenter: Dr. Evan Schwarz
- **Saturday, September 10, 2022 (virtual)** | 8:30a.m. - 12:30p.m. | Presenter: Dr. Fred Rottnek
- **Saturday, December 3, 2022 (virtual)** | 8:30a.m. - 12:30p.m. | Presenter: Dr. Fred Rottnek

PLEASE NOTE: All attendees are required to have a webcam and reliable internet connection. Webcams must be on for the full training in order to be marked as a participant.

**Target Audience:** This activity will assist physicians, nurse practitioners, and physician assistants who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders.

DHSS and SAMSHA has recently updated their regulations regarding the ability to prescribe buprenorphine. The MAT Waiver training offered allows for individuals to prescribe to more than 30 patients in their practice settings. Providers wishing to work with less than 30 clients are able to apply for a waiver immediately by completing a Notice of Intent here: [https://bit.ly/33HSdyf](https://bit.ly/33HSdyf).

For more information on the Practice Guidelines and MAT waiver training requirements please visit the SAMSHA Website at [https://bit.ly/2Qp75P2](https://bit.ly/2Qp75P2).

**Fee:** No Cost

**Educational Objectives:**

- Screen and identify patients with OUD and define evidence-based treatments.
- Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
- Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
- Explain the process of buprenorphine induction as well as stabilization and maintenance.
- Discuss all FDA approved antagonist and agonist medications to treat OUD.
• Discuss basic office protocols including medical record documentation and confidentially.
• Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
• Recognize the importance of obtaining a waiver to begin treating patients with OUD.

*Note: All Half and Half MAT waiver trainings will offer 4 continuing education credits for physicians, nurses, physician assistants, and pharmacists.*

NP & PA’s – this coursework will go toward your 24 hours of training. If you complete this, you can go online and finish the other 16 hours of work to get your certificate. The link below will take you directly to the registration page for the other 16 hours of training

https://e-learning.apna.org/products/medication-assisted-treatment-mat-16-hour-waiver-training

**Ongoing mentorship and support:**

• PCSS-MAT has a comprehensive library of materials with continuing education, available at no cost for healthcare providers. PCSS-MAT also has a no-cost clinical coaching/mentoring program to provide one-on-one clinical expertise for primary care providers. You can post a question to a listserv with an addiction specialist and be matched with an addiction specialist.

**Data Sponsor: AAAP is the DATA 2000 Sponsor of this training**

Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA and Opioid SOR. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.